Clinical Trial VICCMEL1256


A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Vemurafenib (RO5185426) Adjuvant Therapy In Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma At High Risk For Recurrence

Principal Investigator(s)

Jeffrey Sosman


  • Protocol No. VICCMEL1256
  • Open Date: 12/06/2012
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the efficacy of vemurafenib adjuvant treatment administered over a 52-week period in patients with completely resected BRAFV600 mutation positive, cutaneous melanoma, as measured by DFS
  • Disease Sites: Melanoma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: PLX4032; RO5185426 (Vemurafenib); Vemurafenib
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01667419
  • Secondary Protocol No: G027826



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.